Ravi Madan, MD, National Cancer Institute, Bethesda, MD, shares his highlights in prostate cancer from the ASCO 2023 meeting, focusing on a better understanding of patients with DNA damage repair mutations and their outcomes. Quality of life data showed that despite increased toxicity from treatment intensification with PARP inhibitors and a first-line antiandrogen, it did not significantly impact quality of life. However, managing toxicity remains a concern in clinical practice. Additional presentations highlighted worse outcomes in patients with mutations in DNA damage repair pathways. Further follow-up from the TELEPRO-II [NCT02673580] trial revealed benefits and substantial toxicity in patients with mutations. New data on Lutetium with a PARP inhibitor showed interesting preliminary and safety data. Overall, the meeting emphasized the need to better understand the role of PARP inhibitors in first-line metastatic castration-resistant prostate cancer and optimize therapy while balancing patient quality of life and clinical outcomes.This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.